A senior executive at BeiGene is under investigation by Chinese authorities, multiple local media outlets report. The exec is Eva Yin, according to Chinese business news outlets Yicai and Jiemian. Yin ...
China’s leading innovative cancer drugmaker BeiGene Ltd. plans to change its name to BeOne Medicines as part of a rebranding to support its growth ambitions in markets including the US and Europe. The ...
The company’s flagship drug, Brukinsa (zanubrutinib), is among the more recent BTK inhibitors to break into a global market projected to hit $12.2 billion by 2031. Three major players dominate this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results